ClinicalTrials.gg
CompletedNCT00102726Updated Mar 23, 2017

SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy

A Phase 2 interventional study of SB497115 and Placebo in Thrombocytopaenia, sponsored by GlaxoSmithKline. Completed at 95 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-23.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
183
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 53 studies testing eltrombopag in Thrombocytopenia — 2 open to participants now, 3 under way, none of them phase 3. eltrombopag · Thrombocytopenia.

Enrollment
6th of 53
183 · median 40
Started
2005
with 1 other
Phase 2
27 of 53
2 open now
Registered
1st of 53
by date
Lead sponsor
16 of 53
GlaxoSmithKline

Among the 53 studies testing eltrombopag in Thrombocytopenia, this one is the 6th largest by enrollment, is one of 2 that started in 2005, is one of 27 in phase 2, and was the 1st registered.

Thrombocytopenia

484 studies on the registry are indexed under Thrombocytopenia; 102 are open to participants now.

Browse Thrombocytopenia studies →

Open to participants now

2 of the 53 studies testing eltrombopag in Thrombocytopenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About eltrombopag

eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 66 Thrombocytopenia studies recruiting now, 44 (67%) set no upper age limit and 18 (27%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing eltrombopag in Thrombocytopenia, or all of them as a file.
02

Study summary

SB497115 is an oral agent which activates the thrombopoietin receptor and increases platelet counts in healthy volunteers. This study is examining several different doses of SB497115 versus placebo as treatment for patients with advanced solid tumors scheduled to receive chemotherapy with carboplatin and paclitaxel every 21 days. Patients will receive SB497115 on days 2-11 of each 21 day cycle for at least 2 cycles of chemotherapy and for a maximum of 8 cycles of chemotherapy.

Read the detailed description

A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel Group, Dose Ranging Study to Assess the Efficacy, Safety, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist (SB-497115-GR) Administered at 50, 75, and 100 mg to Cancer Patients Receiving Multiple Cycles of Chemotherapy

03

Conditions studied

  • Thrombocytopaenia

Keywords

  • chemotherapy
  • thrombopoietin
  • platelets
  • chemotherapy induced
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects ≥18 years old, who are chemotherapy naïve, with or cytologically confirmed advanced solid tumor (leukemia and lymphoma are excluded) who are scheduled to received carboplatin/paclitaxel as shown below. For the purpose of this study, advanced tumors are defined as tumors that are being treated with palliative intent (i.e., not being treated with curative intent).
  • Subjects scheduled to receive chemotherapy as carboplatin AUC 5-6 IV over 30 minutes plus paclitaxel 175-225 mg/m2 IV over 3 hours on day 1 every 21 days, with routine pre-medications, i.e., 20 mg dexamethasone [or equivalent] orally 6 and 12 hours pre-paclitaxel, 50 mg IV diphenhydramine [or equivalent] and 300 mg IV cimetidine [or equivalent] 30-60 minutes pre-paclitaxel.
  • -Zubrod performance status is 0, or 1.
  • Subject has no history of disorders or dysfunction and no history of a bleeding disorder.
  • Subjects have adequate:

hematologic function ( ≥ 1,500/mm3, ≥ 9 g/dL, and platelet count ≥100,000/mm3 and \< (eg, 400,000 to 450,000/mm3), hepatic function ( ≤ 2 mg/dL and ≤ three times the upper limit of normal), renal function (creatinine ≤ 2.0 mg/dL).

  • Subject has no physical limitation to ingest and retain oral medication.
  • Subject has of at least 6 months.
  • Subject is practicing an acceptable method of (documented in chart). Female subjects (or female partners of male subjects) must either be of nonchildbearing potential (hysterectomy, bilateral oophorectomy, bilateral tubal ligation or > 1 year), or of and use one of the following acceptable methods of contraception from two weeks prior to administration of study medication, throughout the study, and 28 days after completion or premature discontinuation from the study:

Complete abstinence from intercourse; Intrauterine device (IUD); Two forms of barrier contraception (diaphragm plus spermicide, and for males condom plus spermicide); Male partner is sterile prior to entry into the study and is the only partner of the female; Systemic contraceptives (combined or progesterone only).

  • Subject is able to understand and comply with protocol requirements and instructions and intend to complete the study as planned.
  • Subject has signed and dated written .
  • Chemotherapy naive patients with advanced solid tumors (without or rapid progression within 2 weeks) who are scheduled to receive standard first-line therapy with carboplatin and paclitaxel every 21 days.
  • Adequate hematologic, hepatic and renal function.

Exclusion criteria

Exclusion criteria:

  • Any abnormality, other than cancer, identified on the screening examination, or any other medical condition or circumstance, which in the opinion of the Investigator, makes the subject unsuitable for participation in the study and/or would make the patient's data difficult to interpret.
  • Subjects with a known history of rapidly progressive disease (marked increase in tumor size [>50%], ascites, or serious symptoms related to underlying cancer in the preceding 4-week period), surgery within the previous 2 weeks, radiotherapy within the previous 4 weeks, or any prior chemotherapy.
  • Subjects with known pre-existing cardiac disease, including congestive heart failure, arrhythmias requiring treatment, or myocardial infarction within the preceding 3 months.
  • Subjects with abnormal resting 12-lead at screening that would indicate preexisting cardiac disease, as noted in exclusion criterion 3.
  • Subjects with known clotting disorder associated with hypercoaguability.
  • Subject has consumed aspirin, aspirin-containing compounds, salicylates, quinine or non-steroidal anti-inflammatories (NSAIDs) for > 3 consecutive days within 2 weeks of the study start and would require them at any time during the study.
  • Treatment with an drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication.
  • Subject has consumed liquid antacids (e.g. Maalox, Mylanta, Amphogel, milk of magnesia), chewable antacids (e.g. TUMS) or calcium supplements within 48 hours of the first dose of study medication, and/or will require these medications during the study.
  • Subject has consumed rosuvastatin or pravastatin within 1 week of the first dose of study medication and/or will require these medications at any time during the study.
  • Any history of drug-induced thrombocytopenia (e.g., quinine).
  • Systemic anti-coagulant use within 4 weeks prior to study entry.
  • Consumption of any herbal or dietary supplements, excluding vitamin or mineral supplements (See Exclusion 8 for calcium supplements), within 1 week of the study start.
  • Female subjects who are lactating or have a positive beta-hCG at screening.
  • Subjects with a history of or clinical signs or symptoms of brain and/or confirmed by CT or MRI brain scan.
  • History of or bleeding disorders.
  • Patients using aspirin, aspirin-containing compounds, salicylates, antacids, rosuvastatin, pravastatin, non-steroidal anti-inflammatory drugs for greater than 3 days during and within 3 weeks prior to the study.
  • Females who are pregnant or breastfeeding.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
183 participants (actual)

Study arms

  • Active comparator
    Arm 1

    SB-497115-GR 50mg. administered orally daily on days 2 through 11 for each 21-day cycle.

    Drug: SB497115

  • Active comparator
    Arm 2

    SB-497115-GR 75 mg administered orally dailey on days 2-11 of each 21-day cycle.

    Drug: SB497115

  • Active comparator
    Arm 3

    SB-497115 100mg administered orally daily on days 2 through 11 of each 21-day cycle.

    Drug: SB497115

  • Placebo comparator
    Placebo Arm

    Placebo administered orally daily on days 2 through 11 of each 21-day cycle.

    Other: Placebo

Interventions

  • SB497115/Placebo will be administered for at least 2 cycles. Additional cycles are permited if: 1) chemotherapy is continued, 2) the subject appears to be benefitting from the study drug, and 3) the subject has not encountered greater than moderate toxicity with the study drug. The maximum number of cycles would be 8.

  • OtherPlacebo

    Placebo administered orally daily on days 2 through 11 of each 21-day cycle.

06

What researchers measure

Primary outcomes

  1. Change in baseline platelet count from the first day of the second cycle of chemotherapy to the lowest count observed (nadir) during the cycle(21 days)

    Time frame: throughout entire study

Secondary outcomes

  1. Safety and tolerability, pharmacodynamics, changes in platelet count during cycle 1(21 days) and beyond cycle 2(21 days), population PK, and deliver intended doses of chemotherapy without thrombocytopenia related AEs

    Time frame: Throughout entire study

  2. Safety and tolerability as indicated by physical exam, 12-lead ECGs, ophthalmologic examinations, clinical laboratory tests, clinical monitoring/observation, and AE reporting

    Time frame: throughout study

  3. Pharmacodynamic parameters including platelet count, grade of thrombocytopenia,serum thrombopoietin, and platelet aggregation/activation during the first and second cycles of carboplatin/paclitaxel

    Time frame: During first and second cycles of carboplatin/paclitaxel

  4. Change in platelet count from day 1 (baseline) to nadir during the first cycle and beyond the second cycle of carboplatin/paclitaxel

    Time frame: throughout study

  5. Population PK of SB-497115, including clearance (CL/F), absorption rate constant(ka), and volume of distribution (V/F) with assessment of demographic covariates influencing SB-497115 PK

    Time frame: throughout study

  6. The relationship between PK of SB-497115 andrelevant safety and efficacy endpoints will be explored

    Time frame: throughout study

  7. Dose intensity (percent of intended dose) of carboplatin/paclitaxel

  8. Carboplatin/paclitaxel-associated thrombocytopenia-related AEs, as defined by NCI

  9. Common Terminology Criteria for Adverse Events, CTCAE v3.0, to include the number of platelet transfusions, bleeding events (hematoma), hemorrhage/bleeding,petechiae/purpura), clinical laboratory tests, and clinical observations

    Time frame: throughout study

07

Study locations

95 sites
  • GSK Investigational Site
    Tucson, Arizona 85715, United States
  • GSK Investigational Site
    Jonesboro, Arkansas 72401, United States
  • GSK Investigational Site
    Greenbrae, California 94904-2007, United States
  • GSK Investigational Site
    Long Beach, California 90813, United States
  • GSK Investigational Site
    Los Angeles, California 90033, United States
  • GSK Investigational Site
    Los Angeles, California 90095, United States
  • GSK Investigational Site
    Colorado Springs, Colorado 80907, United States
  • GSK Investigational Site
    Newark, Delaware 19718, United States
  • GSK Investigational Site
    Boca Raton, Florida 33428, United States
  • GSK Investigational Site
    Hollywood, Florida 33021, United States
  • GSK Investigational Site
    Tamarac, Florida 33321, United States
  • GSK Investigational Site
    Savannah, Georgia 31405, United States
  • GSK Investigational Site
    Metairie, Louisiana 70006, United States
  • GSK Investigational Site
    Baltimore, Maryland 21237-3998, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55455, United States
  • GSK Investigational Site
    Hattiesburg, Mississippi 39401, United States
  • GSK Investigational Site
    Tupelo, Mississippi 38801, United States
  • GSK Investigational Site
    Las Vegas, Nevada 89102, United States
  • GSK Investigational Site
    Babylon, New York 11702, United States
  • GSK Investigational Site
    New York, New York 10032, United States
  • GSK Investigational Site
    Durham, North Carolina 27707, United States
  • GSK Investigational Site
    Akron, Ohio 44304, United States
  • GSK Investigational Site
    Mayfield Heights, Ohio 44124, United States
  • GSK Investigational Site
    Toledo, Ohio 43614-5809, United States
  • GSK Investigational Site
    Bryan, Texas 77802, United States
  • GSK Investigational Site
    Ogden, Utah 84403, United States
  • GSK Investigational Site
    Salem, Virginia 24153, United States
  • GSK Investigational Site
    Capital Federal, Buenos Aires C1405BCK, Argentina
  • GSK Investigational Site
    La Plata, Buenos Aires 1900, Argentina
  • GSK Investigational Site
    Rosario, Santa Fe 2000, Argentina
  • GSK Investigational Site
    Rosario, Santa Fe S2000KZE, Argentina
  • GSK Investigational Site
    Buenos Aires, 1425, Argentina
  • GSK Investigational Site
    Buenos Aires, C1416DRW, Argentina
  • GSK Investigational Site
    Vienna, A-1090, Austria
  • GSK Investigational Site
    Vienna, A-1100, Austria
  • GSK Investigational Site
    Vienna, A-1140, Austria
  • GSK Investigational Site
    Plovdiv, 4000, Bulgaria
  • GSK Investigational Site
    Sofia, 1527, Bulgaria
  • GSK Investigational Site
    Sofia, 1756, Bulgaria
  • GSK Investigational Site
    Sofia, 1784, Bulgaria
  • GSK Investigational Site
    Brno, 656 53, Czech Republic
  • GSK Investigational Site
    Praha 8, 180 81, Czech Republic
  • GSK Investigational Site
    Freiburg, Baden-Wuerttemberg 79106, Germany
  • GSK Investigational Site
    Regensburg, Bayern 93049, Germany
  • GSK Investigational Site
    Marburg, Hessen 35033, Germany
  • GSK Investigational Site
    Hemer, Nordrhein-Westfalen 58675, Germany
  • GSK Investigational Site
    Trier, Rheinland-Pfalz 54290, Germany
  • GSK Investigational Site
    Grosshansdorf, Schleswig-Holstein 22927, Germany
  • GSK Investigational Site
    Bad Berka, Thueringen 99437, Germany
  • GSK Investigational Site
    Berlin, 13353, Germany
  • GSK Investigational Site
    Hamburg, 21075, Germany
  • GSK Investigational Site
    Budapest, 1529, Hungary
  • GSK Investigational Site
    Székesfehérvár, 8000, Hungary
  • GSK Investigational Site
    Bangalore, 560 034, India
  • GSK Investigational Site
    Hyderabad, Andhra Pradesh, 500482, India
  • GSK Investigational Site
    Kolkatta, 700 054, India
  • GSK Investigational Site
    Vellore, 632 004, India
  • GSK Investigational Site
    Benevento, Campania 82100, Italy
  • GSK Investigational Site
    Roma, Lazio 00168, Italy
  • GSK Investigational Site
    Milano, Lombardia 20141, Italy
  • GSK Investigational Site
    Campobasso, Molise 86100, Italy
  • GSK Investigational Site
    Seoul, 135-710, Korea, Republic of
  • GSK Investigational Site
    Seoul, 138-736, Korea, Republic of
  • GSK Investigational Site
    Merida, Yucatán 97500, Mexico
  • GSK Investigational Site
    Lima, Lima 34, Peru
  • GSK Investigational Site
    Olsztyn, 10-228, Poland
  • GSK Investigational Site
    Poznan, 60-569, Poland
  • GSK Investigational Site
    Poznan, 61-866, Poland
  • GSK Investigational Site
    Szczecin, 70-891, Poland
  • GSK Investigational Site
    Wroclaw, 53-413, Poland
  • GSK Investigational Site
    Bucuresti, 022328, Romania
  • GSK Investigational Site
    Moscow Region, 143 423, Russian Federation
  • GSK Investigational Site
    Moscow, 115 478, Russian Federation
  • GSK Investigational Site
    Moscow, 117997, Russian Federation
  • GSK Investigational Site
    Moscow, 129301, Russian Federation
  • GSK Investigational Site
    St. Petersburg, 197758, Russian Federation
  • GSK Investigational Site
    St. Petersburg, 198255, Russian Federation
  • GSK Investigational Site
    Badalona, 08916, Spain
  • GSK Investigational Site
    Barcelona, 08036, Spain
  • GSK Investigational Site
    Cordoba, 14004, Spain
  • GSK Investigational Site
    Madrid, 28006, Spain
  • GSK Investigational Site
    Santa Cruz de Tenerife, 38320, Spain
  • GSK Investigational Site
    Santander, 38008, Spain
  • GSK Investigational Site
    Sevilla, 41014, Spain
  • GSK Investigational Site
    Taipei, 100, Taiwan
  • GSK Investigational Site
    Tau-Yuan County, 333, Taiwan
  • GSK Investigational Site
    Dnepropetrovsk, 49102, Ukraine
  • GSK Investigational Site
    Donetsk, 83092, Ukraine
  • GSK Investigational Site
    Kyiv, 03115, Ukraine
  • GSK Investigational Site
    Lvov, 79031, Ukraine
  • GSK Investigational Site
    Truro, Cornwall TR1 3LJ, United Kingdom
  • GSK Investigational Site
    Chelmsford, Essex CM1 7ET, United Kingdom
  • GSK Investigational Site
    Colchester, CO3 3NB, United Kingdom
  • GSK Investigational Site
    Dundee, DD1 9SY, United Kingdom
  • GSK Investigational Site
    Leicester, LE1 5WW, United Kingdom
08

References and documents

Publications

  • Hayes S, Mudd PN Jr, Ouellet D, Johnson BM, Williams D, Gibiansky E. Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia. Cancer Chemother Pharmacol. 2013 Jun;71(6):1507-20. doi: 10.1007/s00280-013-2150-9. Epub 2013 Apr 6. PubMed 23564375 ↗
  • Kellum A, Jagiello-Gruszfeld A, Bondarenko IN, Patwardhan R, Messam C, Mostafa Kamel Y. A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors. Curr Med Res Opin. 2010 Oct;26(10):2339-46. doi: 10.1185/03007995.2010.510051. PubMed 20735290 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2005, a primary completion of Feb 2007 and a completion of Feb 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2005
First posted
Feb 2, 2005
Start
Feb 2005
Primary completionActual
Feb 2007
CompletionActual
Feb 2007
Last update
Mar 23, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00102726
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Feb 2, 2005
Start date
Feb 2005
Primary completion
Feb 2007
Completion
Feb 2007
Last update
Mar 23, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eltrombopag

Start the discussion